DEXMEDETOMIDINE IS A new intravenous drug gaining popularity in neuroanesthesia and neurocritical care practice. This ␣ 2 -adrenergic receptor agonist offers a unique "cooperative sedation," anxiolysis, and analgesia with no respiratory depression. Cerebral effects are generally consistent with a desirable neurophysiological profile, including neuroprotective characteristics. In addition, sympatholytic and antinociceptive properties allow for hemodynamic stability at critical moments of neurosurgical stimulation. This review will address the neuropharmacology and neurophysiology of ␣ 2 -adrenergic agonists and will specifically consider the rapidly evolving applicability of dexmedetomidine as an adjuvant to neurosurgical case management.
D
exmedetomidine (DEX) (Precedex; Hospira, Inc., Lake Forest, IL) is a highly selective ␣ 2 -adrenoreceptor agonist recently introduced to anesthesia practice. It produces dose-dependent sedation, anxiolysis, and analgesia (involving spinal and supraspinal sites) without respiratory depression (48, 58) . ␣ 2 -Agonists are known to reduce anesthetic requirements and, because of sympatholytic properties, to afford hemodynamic stability during the intraoperative period (46) . These clinical characteristics make this intravenous agent a potentially attractive adjunct for neuroanesthesia and in the neurological intensive care unit (ICU). When a new drug is introduced into neuroanesthesia practice, however, several concerns must be addressed. Principal considerations include the ability of a drug to preserve intracranial homeostasis, to allow a hemodynamically stable perioperative course, to be compatible with neurophysiological monitoring, and to ensure rapid emergence to a level of consciousness permitting neurological assessment in the operating room. Additional desirable end points would include cerebral blood volume reduction (helping to minimize operative brain retraction), an optimization of the cerebral oxygen supply and demand relationship, and neuroprotection. The following review discusses the pharmacology, central nervous system (CNS) effects, current clinical applications, and the specific therapeutic role of DEX in patients undergoing neurosurgical procedures.
CLINICAL PHARMACOLOGY
␣ 2 -Adrenoreceptors are a subgroup of noradrenergic receptors distributed broadly within and outside the CNS. ␣ 2 -Receptors in the brain are concentrated primarily in the pons and medulla, areas involved in transmitting sympathetic nervous system activation from higher brain centers to the periphery. Stimulation of presynaptic ␣ 2 -receptors reduces norepinephrine release, and activation of postsynaptic ␣ 2 -receptors hyperpolarizes neural membranes. Interaction between these receptors and norepinephrine thus acts as an inhibitory feedback loop in which excessive norepinephrine release actually reduces further release of the same neurotransmitter (19, 73) . In the spinal cord, ␣ 2 -adrenergic receptors are located postsynaptically in the dorsal horn, and their stimulation inhibits nociceptive signal transmission (40) . In the periphery, ␣ 2 -receptors are found on vascular smooth muscle, in which their activation results in vasoconstriction (73) .
Drugs that stimulate ␣ 2 -adrenergic receptors produce a variety of physiological effects. Compared with clonidine, DEX is a more specific and selective ␣ 2 -adrenergic receptor agonist with a shorter elimination half-life. The most prominent clinical effects of DEX are described below.
Anxiolysis and Sedation
DEX seems to exert its sedative and anxiolytic effects through activation of ␣ 2 -adrenoreceptors in the locus ceruleus (LC), a major site of noradrenergic innervation in the CNS. The LC has been implicated as a key modulator for a variety of critical brain functions, including arousal, sleep, anxiety, and drug withdrawal syndromes associated with CNS depressants, such as opioids (13) . The sedation produced by ␣ 2 -adrenoreceptor agonists, unlike that produced by traditional sedatives, such as benzodiazepines and propofol, does not depend primarily on activation of the ␥-aminobutyric acid (GABA) system. Furthermore, the primary site of ␣ 2 -agonist sedative action does not seem to be the cerebral cortex, as would be the case with GABA-mimetic drugs (67) .
Perhaps because of a noncortical site of action, ␣ 2 -agonists seem to engender a different type of sedation compared with GABA-mimetic drugs. DEX produces an unusually cooperative form of sedation, in which patients easily transition from sleep to wakefulness and task performance when aroused, and then back to sleep when not stimulated (57, 89) . Furthermore, disinhibition, cited as a common problem for propofol and the benzodiazepines, has not been described for DEX. Given that DEX seems to exert its sedative action at the LC, a brain wakefulness and anxiety center, it is possible that cognitive compromise and accompanying disinhibition are less prominent. This theory is consistent with data from healthy volunteers indicating that cognitive integrity is well preserved in patients receiving DEX (26, 39) . Additional supportive evidence comes from primate-based investigations showing that in some scenarios, ␣ 2 -agonists may actually be procognitive, improving some higher brain functions from the baseline unmedicated state (4, 25) .
Analgesia
␣ 2 -Agonists have been recognized as having significant analgesic effects. DEX has been shown to consistently reduce opioid requirements by 30 to 50% (1, 90) . The analgesic potential of ␣ 2 -agonists, however, does not approximate the potency of opioids (44) . Nevertheless, in certain types of pain in which opioid relief is suboptimal, such as in neuropathic pain, ␣ 2 -agonists may offer specific advantages (95) .
The precise mechanisms and pathways by which drugs in this class induce analgesia have not been fully elucidated. Brain, spinal cord, and peripheral mechanisms all seem operant. The most important of these sites may be the spinal cord, where the activation of ␣ 2C -receptor subtype seems to accentuate the analgesic actions of opioids in attenuating the transmission of nociceptive signals to brain centers (27) .
Cardiovascular Effects
The hemodynamic effects of DEX result from peripheral and central mechanisms. The ␣ 2B -receptors located on vascular smooth muscle mediate vasoconstriction. The initial response to rapid DEX infusion may be a transient hypertension (16, 48) . In the CNS, activation of ␣ 2 -receptors leads to a reduction in sympathetic outflow and an increase in vagal activity. In addition, DEX may have some action as a peripheral ganglionic blocker, further enhancing the sympatholytic effect (60) . The net effect of ␣ 2 -adrenoreceptor action is a significant reduction in circulating catecholamines, modest reduction in blood pressure, and modest reduction in heart rate (80, 82) . Although hypotension has been described in patients receiving DEX, this exaggerated physiological effect seems to have a frequent temporal relationship to the use of a loading dose and/or preexisting hypovolemia (45) . Bradycardia has also been described, primarily in younger patients with high levels of vagal tone. DEX is not recommended for patients diagnosed with heart block. The use of ␤-blockade does not seem to increase the risk of bradycardia (10) .
The well-understood sympatholytic effects of this class of drugs, perhaps coupled with their ability to control shivering, relieve pain, and reduce anxiety, led to the consideration that ␣ 2 -adrenoreceptor agonists may prove useful as myocardial protectants. Animal studies, as well as a recent meta-analysis, suggest that this class of drugs may significantly reduce the risk of cardiac-related mortality (53, 93) .
Effects on Ventilation
␣ 2 -Adrenoreceptor agonists have minimal effects on ventilation (12, 57) . In healthy volunteers, as well as intraoperatively, even very high doses of DEX did not compromise respiratory function. Respiratory rates actually trended upward throughout the dose escalation that eventually reached 14 times the therapeutic plasma level (26) . There was no significant difference between placebo and DEX in measures of respiratory function after extubation in the group of ICU patients (92) . The lack of respiratory depression, as measured by pulse oximetry and PaCO 2 , was also demonstrated in patients sedated with DEX, which was administered at infusion rates 10 to 15 times higher than maximally recommended (70) . The benign effect of this class of drugs on ventilatory drive may be underscored by the approval of DEX by the Food and Drug Administration as the only critical care sedative recommended for continuous use after extubation.
Endocrine and Renal Effects
␣ 2 -Adrenoreceptor agonists attenuate responses to stress, including neurohumoral responses. Use of DEX for less than 24 hours does not seem to significantly reduce serum cortisol levels (91) . Because of the chemical resemblance of the drug to etomidate, the concern arose that the reduced cortisol responses may result from a decreased corticosteroid synthesis. Although long-term data are not yet available, DEX administration for up to 7 days in dogs failed to suggest any adrenal shock or severe impairment of the hypothalamic-pituitary axis (59) .
DEX seems to induce diuresis in animal models studied, possibly through an ability to reduce efferent sympathetic outflow of the renal nerve (94) . In addition, DEX has been shown to suppress antidiuretic hormone, with a resulting diuretic effect, but it remains unclear whether this effect is attributable in any part to improved renal perfusion (37) . Finally, DEX increases secretion of atrial natriuretic peptide, resulting in natriuresis (63) .
NEUROPHYSIOLOGICAL EFFECTS OF DEX
Cerebral Blood Flow and Metabolism ␣ 2 -Adrenergic receptors are widely distributed within the cerebral vasculature (18, 33) . Much work on the adrenergic regulation of the cerebral circulation has focused on the extrinsic sympathetic innervation of arteries and pial vessels. ␣ 2 -Agonist stimulation of these receptors has demonstrated vasoconstriction in isolated cerebral vessels and in various animal models (6, 35, 43) . Moreover, the inability of locally applied atipamezole (an ␣ 2 -antagonist) to substantially inhibit the vasoconstrictor response to systemically administered DEX suggests that ␣ 2 -agonists might also cause vasoconstriction indirectly through actions at other sites in the CNS (5). Of note, noradrenergic neurons in the LC project widely throughout the brain, also targeting the intracerebral capillaries and microarterioles (i.e., intrinsic adrenergic innervation) (23) . Thus, systemic administration of ␣ 2 -agonists could decrease cerebral blood flow (CBF) via direct ␣ 2 -mediated vascular smooth muscle constriction and indirectly via effects on the intrinsic neural pathways modulating vascular effects.
Investigations of the effect of LC activation (i.e., increases in noradrenergic neural firing) or ablation on local CBF seem discrepant, on the basis of low-to high-frequency activation and species differences, but for in vivo physiological conditions or chemical stimulation, LC-mediated vasoconstriction prevails (71) . DEX decreases the firing rate of LC neurons, and hence, vasodilatory increases in CBF might be expected.
Nevertheless, Karlsson et al. (47) and Zornow et al. (96) documented that 10 g/kg of DEX caused a reduction in CBF (40-45%) in halothane-and isoflurane-anesthetized dogs, respectively. This marked decrease in CBF was not accompanied by a proportional decrease in cerebral metabolic rate (CMRO 2 ).
Fale et al. (30) demonstrated that systemic administration of DEX decreased normocapnic and hypercapnic CBF in dogs anesthetized with isoflurane but had no CBF effect under pentobarbital anesthesia. CBF reactivity to hypercapnia was nevertheless maintained. McPherson et al. (62) evaluated the effect of DEX on CBF response to hypoxia in isoflurane-anesthetized dogs and found that the vasodilatory response to hypoxia was maintained proportional to the decreased normoxic levels but was still lower than in controls. Thus, although cerebral O 2 transport was reduced 30% by DEX, this reduction remained constant during hypoxia because of the CBF increase, and without a reduction in CMRO 2 . Furthermore, the reduction in CBF by DEX is independent of nitric oxide synthesis.
Human studies are consistent with the results of animal experiments. Lee et al. (54) measured middle cerebral artery blood flow velocity by use of transcranial Doppler sonography in healthy volunteers after administration of clonidine and showed a significant decrease in middle cerebral artery blood flow velocity. Using a similar technique, Zornow et al. (97) reported dose-dependent decreases in CBF at four steady-state concentrations of DEX. Recent measurements of regional and global CBF by use of positron emission tomography confirmed reduction in CBF by 30% at clinically relevant concentrations (69). Lam et al. (51) similarly demonstrated reductions in middle cerebral artery blood flow velocity in healthy volunteers with DEX administration, with preservation of CO 2 reactivity and cerebral autoregulation. In contradistinction to the noted decrease in CBF with systemic DEX or clonidine dosing, intrathecal infusion of clonidine produced an increase in CBF velocities, and cold pressor testing activation of the LC showed a decreased response (17) . These findings seem more compatible with the tonic vasoconstrictive role for the LC outlined earlier. It is therefore important to recognize that the intrinsic and extrinsic systems are not isolated, unrelated systems. Stimulation of the afferent baroreceptors and changes in arterial pressure can affect LC neuronal firing and consequently modulate sympathetic outflow.
As outlined earlier, background anesthetic regimens may affect the net cerebrovascular vasoreactive responses to DEX administration (30, 47, 62) . Cerebrovascular dilation induced by either isoflurane or sevoflurane is less with DEX pretreatment (68) . Thus, ␣ 2 -agonists might be useful adjuncts to inhalational anesthetics (cerebral vasodilators) during neurosurgery in situations in which an increase in CBF should be avoided (i.e., traumatic brain injury, large brain tumors). With subarachnoid hemorrhage, the increase in circulating catecholamines and massive sympathetic outflow has been shown to contribute to cerebral vasospasm, and blocking this adrenergic effect may be protective (66).
Despite studies demonstrating neuroprotective effects of DEX in models of ischemic brain injury, the aforementioned animal studies have nevertheless raised concerns that DEX may reduce CBF without decreasing CMRO 2 , potentially limiting adequate cerebral oxygenation of brain tissue at risk for ischemic injury. Clinical circumstances would determine the significance of the CBF decrease. Despite the large reduction in CBF in the face of an unaltered CMRO 2 , there was no evidence of global cerebral ischemia in dogs (97) . The CMRO 2 effect of DEX administration has not been investigated in humans. However, Sturaitis et al. (78) , in a preliminary study evaluating the effect of DEX on brain tissue oxygenation in patients undergoing cerebrovascular surgery, found that even under circumstances of baseline cerebrovascular compromise and hyperventilation, DEX seemed to have no detrimental effect on local brain tissue oxygenation. In summary, under normotensive conditions, the effect of DEX in the setting of compromised cerebral circulation has thus far evidenced no apparent adverse effects.
Intracranial Pressure
Increases in intracranial pressure (ICP) can be detrimental during neurosurgical procedures. A reduction in cerebral per-fusion pressure may lead to global or regional ischemia. Internal pressure gradients may be created, producing intracranial brain herniation or external herniation of the brain substance. Surgery under these conditions is particularly difficult, often requiring considerable retraction for adequate operative field exposure. ␣ 2 -Agonists are more potent vasoconstrictors on the venous than on the arteriolar side of the cerebral vasculature (87) . Because the venous compartment comprises most of the cerebral blood volume, ␣ 2 -agonists could presumably decrease ICP without greatly increasing arteriolar cerebrovascular resistance. McCormick et al. (61) found a significant dose-dependent decrease in ICP after treatment with the ␣ 2 -agonist xylazine in a model of intracranial hypertension in dogs. Clinical trials as to the effect of the ␣ 2 -agonists on ICP in head-injured patients, however, have not reflected these observations (84) . A minimal effect on ICP was also reported for clonidine in patients with brain tumors (32) .
In normocapnic rabbits without intracranial pathological conditions, DEX at low doses transiently decreases ICP by 30% (98) . In the high-dose DEX group, ICP remained unchanged despite a significant increase in arterial blood pressure, and it is likely that systemic hypertension counteracted the decrease in ICP observed with low doses. DEX did not alter ICP in rabbits with cryogenically induced space-occupying lesions. In the only human study examining the issue, Talke et al. (83) found that DEX administration to patients after transsphenoidal hypophysectomy had no effect on lumbar cerebrospinal fluid pressures.
Effect on EEG
The anesthetic agents suitable for perioperative monitoring of ischemia and seizures should have minimal effects on the electroencephalogram (EEG). The ␣ 2 -agonists attenuate the ␣ and ␤ fractions and total power of an EEG as well as increased slow-wave activity (14, 65) . This pattern is typically seen with increasing depth of anesthesia. Although the EEG changes produced by ␣ 2 -agonists are qualitatively similar to those produced by other agents, there is an important difference in their mechanisms of action. The preponderance of the lowerfrequency and ␦ bands, typically seen with increasing depth of inhalational anesthesia, that are observed with most inhalational agents is primarily the result of a direct suppression of the cortical activity. ␣ 2 -Agonists, however, act by interrupting noradrenergic neurotransmission and, subsequently, by disinhibiting the inhibitory interneurons in the LC. As discussed earlier, the LC is the predominant noradrenergic nucleus in the brain, has a number of efferent connections, particularly to the frontal lobes, and is an important modulator of wakefulness. DEX (20 g/kg) and halothane (1-2%) produced quantitatively similar EEG changes in chronically instrumented cats (31) . However, halothane resulted in unconsciousness and a lack of response to tail clamping, whereas DEX produced profound sedation with preservation of the tail-clamp response. In humans, the infusion of DEX at 0.6 g/kg/h produced EEG changes that correspond to a bispectral index of 60 (moderate to deep sedation) (39) . The volunteers, however, were readily awakened simply by talking to them. The results of these studies suggest that processed EEG parameters may be inadequate to assess the depth of anesthesia in the presence of ␣ 2 -agonists.
Intraoperative electrocorticography requires that an anesthetic will not interfere with EEG monitoring of seizure spikes, and agents that reduce seizure threshold may result in falsepositive localization of seizure focus. DEX reduces seizure threshold in various animal models, suggesting facilitation of seizure expression by the inhibition of central noradrenergic transmission (64, 65) . The clinical significance of these findings is unclear, because there are no reports of unanticipated seizures in humans. In fact, DEX was used successfully in patients with known epilepsy for awake craniotomy (2, 11) .
The only human study in which electrocorticographic responses during asleep craniotomy for seizure focus resection were investigated demonstrated that under the neuroanesthetic conditions studied (a lightly anesthetized state with combined DEX and sufentanil infusions and no volatile agent), marked alterations in electrocorticographic background activity compared with preoperative subdural EEG recordings were noted, and epileptiform activity was suppressed. Small, repeated bolus doses of etomidate elicited epileptiform activity over epileptogenic cortex in most patients (75) . In contrast, in patients undergoing awake EEG monitoring, epileptiform activity did not seem to be suppressed and may have been enhanced in some patients (36) . Thus, adjuvant anesthetic agents, dose administration, and possibly the awake state may modify the EEG and seizure threshold with DEX.
Effect on Evoked Potentials
The anesthetic agent useful in neurosurgery should not interfere with perioperative neurophysiological monitoring. A carefully conducted study in rats confirmed the preservation of the cortical somatosensory evoked potential at clinical and supraclinical concentrations of DEX (7) . A study in human volunteers demonstrated that, in contrast to most anesthetics, DEX does not decrease cortical responses (85) . The authors hypothesized that the lack of effect on cortical evoked responses results from indirect cortical depression caused by reduced activity from subcortical areas. In two patients undergoing cervico-occipital fusion, DEX maintained technically adequate conditions for somatosensory evoked potential monitoring (15) . In a study by Sturaitis et al. (74) , the intraoperative adjuvant administration of DEX in patients undergoing craniotomy for tumor or aneurysm had a minimal effect on cortical somatosensory evoked potential amplitudes or latencies. In addition, during DEX infusion, no significant changes were seen in the patients undergoing sodium thiopental EEG burst suppression. The same investigators looked at the effect of DEX on flash electroretinogram and visual evoked potential monitoring during ophthalmic artery aneurysm Guglielmi de-tachable coiling and clipping and found the recordings to be reliable, with minimal effects on electroretinogram responses and with perhaps a tendency for visual evoked potential responses to be less delayed and less decreased in amplitude (76) . Hence, DEX allows for consistent and reliable neurophysiological monitoring in circumstances in which neural tissue is at risk for injury.
Neuroprotection
Cerebral ischemia is associated with an increase in circulating and extracellular brain catecholamine concentrations. Interventions to reduce sympathetic tone improved neurological outcome (38, 50) . Thus, the treatment with agents that reduce the release of norepinephrine in the brain (e.g., ␣ 2 -agonists) may provide protection against the damaging effect of cerebral ischemia. Several studies have shown that DEX improves neuronal survival after transient global or focal cerebral ischemia in the rat (41, 49, 56) . The exact mechanism of the neuroprotective effect of the ␣ 2 -agonists, however, is unclear. Engelhard et al. (28) showed that DEX does not suppress the intraischemic increase of cerebral extracellular catecholamines. They questioned the hypothesis that the neuroprotective effects of DEX are related to inhibition of cerebral catecholamines. They suggested that the neuroprotection offered by DEX is a result of modulation of the balance between proapoptotic and antiapoptotic proteins (29) .
Several studies demonstrate that ␣ 2 -adrenoreceptor agonists reduce excitatory neurotransmitter (e.g., glutamate) release (22, 81) . High levels of glutamate depolarize the neuronal membrane and allow calcium to enter into the cell, thus triggering a number of events that lead to the cellular damage. Agents that reduce glutamate release are thus considered neuroprotective.
Huang et al. (42) showed that DEX enhances glutamine disposal by oxidative metabolism in astrocytes. This effect occurs at pharmacologically relevant concentrations and is large enough to reduce the availability of glutamine as a precursor of neurotoxic glutamate. Laudenbach et al. (52) found that both clonidine and DEX protected against excitotoxic injury to the developing brain.
CLINICAL APPLICATION Functional Neurosurgery
Intracranial surgical procedures are often limited by the location and spatial extent of the lesion (i.e., near speech, motor, or sensory cortex) and its relationship to functioning tissue. The surgeon must often balance the benefits of an aggressive resection with anticipated neurological dysfunction. Intraoperative neurophysiological testing is often required to verify that the surgical target has been localized or to assess the effect of producing the intended functional change. Hence, these procedures often require patient cooperation for functional assessment.
Drugs administered for these operations should allow for a rapid change in the level of sedation and analgesia to provide an adequate level of sedation and analgesia during periods of intense surgical stimulation (e.g., scalp incision, bone flap removal, dural dissection) but have the patient awake and cooperative during functional testing. A combination of local anesthesia and conscious sedation with a variety of agents, such as propofol, midazolam, and short-acting opioids, has generally proved successful in most cases. However, concerns have been raised regarding disinhibition and lack of cooperation, pain, oversedation, respiratory depression, and airway obstruction.
DEX may be an attractive alternative or adjunct to the currently used anesthetic techniques. The properties of DEX include sedation, analgesia, and a demonstrable anestheticsparing effect. It does not suppress ventilation. Low-dose infusion of this drug provides sedation that can be easily reversed with verbal stimulation.
Bekker et al. (11) reported on the first application of DEX for intraoperative language mapping in a patient undergoing left temporal neoplasm resection. The authors used a sleepawake-sleep technique. DEX was the sole agent for the awake portion of the procedure. The pharmacology of DEX allowed the authors to achieve a level of sedation and analgesia sufficient to complete the required neuropsychiatric testing, as well as to perform an awake tumor resection. The same group described the use of DEX for brain mapping of the cortical speech area and resection of the epileptic foci in a 12-year-old child (2) . Recently published reports documented the advantages, hemodynamic changes, and complications associated with the use of DEX for awake craniotomy in three centers (3, 34, 55) . The authors of these case series state that DEX infusion at a low rate (0.1-0.3 g/kg/h) may be helpful for intraoperative functional testing in procedures in which sedation and mild analgesia are the only anesthetic requirements.
Stereotactic implantation of deep brain stimulators for movement disorders represents a challenge for surgeons and anesthesiologists. Most commonly used sedatives may suppress tremor (e.g., propofol) or affect microelectrode recording that is used for precise localization of the surgical target. The use of DEX for deep brain stimulator placement improved patient satisfaction without compromising target localization (72) . It also reduced the use of antihypertensive drugs. The largest experience to date with the use of DEX sedation for deep brain stimulator placement in more than 80 patients (79) has proved this therapy to be safe, with good hemodynamic control, minimal use of antihypertensive intervention, and no respiratory compromise, while offering ease of neurological examination and patient satisfaction. Their technique titrates DEX loading doses, infusion rates, and supplemental opioids to changing patient or surgical needs, with adjustments made for evidenced tremor or hypertonicity, and yet with minimal effects noted on the intraoperative single-cell recordings. One patient with first-degree heart blockage, however, experienced transient asystole associated with seizure at dural incision and consistent with potentiation of the known cardiac conductivity side effects of DEX.
Of significant impact is the use of DEX in the magnetic resonance imaging suite, where stereotactic frame placement and accurate imaging in tremulous Parkinson's patients makes remote-location anesthetic management challenging. In such circumstances, in lieu of general anesthesia or the deep propofol sedation needed to prevent motion artifact, DEX remains a safe alternative, offering a sedation that minimizes movement, causes no respiratory depression, and has no significant residual effects on subsequent intraoperative recordings (79) .
DEX has also been used successfully for sedating patients undergoing awake carotid endarterectomy, permitting intraoperative neurological examination (9) . This prospective, randomized, double-blind study demonstrated that the use of DEX resulted in less fluctuation from the desired sedation level intraoperatively compared with the control group (midazolam/fentanyl/propofol management). Furthermore, patients sedated with DEX were comfortable and cooperative and had a lower incidence of postoperative hypertension than patients in the control group. Although more patients in the DEX group required intraoperative arterial shunts, the difference was not statistically significant. The authors suggest further investigation of the effect of DEX on CBF in patients with compromised cerebral circulation.
Intracranial Procedures
The intense surgical stimuli associated with craniotomy frequently engender sympathetic activation and marked changes in systemic arterial pressure, CBF, and ICP. Cerebrovascular responses may result in elevated ICP and reduction in cerebral perfusion pressure, especially in patients with impaired autoregulation and compromised cerebral compliance. Perioperative hypertension in neurosurgical patients is associated with intracranial bleeds and prolonged hospital stay (8) . Thus, the prevention and control of the hemodynamic response to nociceptive stimuli are of utmost importance to preserve cerebral homeostasis in neurosurgical patients. Even with current neuroanesthesia management, hemodynamic stability may be challenging, especially in hypertensive patients.
The antinociceptive, sympatholytic, and anesthesia-sparing effects of ␣ 2 -agonists are well documented (46, 48) . This spectrum of properties would be consistent with the important goals during neurosurgical anesthesia of intraoperative hemodynamic stability and modulation of intraoperative sympathetic responses to attenuate cerebrovascular and myocardial risks and avoid intracranial hemorrhage, and to allow immediate neurological evaluation upon emergence. Oral premedication with clonidine blunted hypertensive responses to intubation or pin head-holder application compared with placebo (20, 86) but increased the incidence of hypotension after induction of anesthesia in older patients (86) . Favre et al. (32) studied the effect of intravenous clonidine pretreatment on ICP and on the hemodynamic responses to nociceptive stimuli in patients undergoing craniotomy under total intravenous anesthesia. In patients with a baseline ICP lower than 20 mm Hg, clonidine had no effect on ICP, and mean arterial pressure and cerebral perfusion pressure decreased to lower values than those recorded in the placebo group without altering the increase in these variables after intraoperative noxious stimulation. Costello and Cormack (24) compared the hemodynamic effects of oral clonidine with those of temazepam, a benzodiazepine derivative with similar sedative and anxiolytic properties. Clonidine was effective in reducing the mean arterial pressure increase with pin head-holder application in patients undergoing craniotomy.
Preliminary data on the perioperative use of DEX in patients undergoing craniotomy for brain tumor under general anesthesia indicate that the intraoperative administration of DEX is opioid-sparing, results in less need for antihypertensive medication, and may offer greater hemodynamic stability at incision and emergence (77) . Our personal experience with DEX shows that this stability is most notable vis-à-vis the challenging emergence hypertension seen with neurovascular procedures. A blinded, placebo-controlled study examining the effect of DEX on perioperative hemodynamic stability in patients undergoing craniotomy for a broader range of clinical conditions (tumor, epilepsy, neurovascular, etc.) is currently underway in our institutions.
Spinal Surgery
Postoperative neurological assessment of a patient after an extensive spinal fusion is critical to detect new neurological deficits. Although the majority of these patients can be safely extubated immediately on awakening, some of them are left intubated, especially after cervical procedures in the prone position. Reintubation of these patients is extremely difficult should postoperative respiratory compromise occur. The ideal sedation level would permit sequential neurological evaluation but minimize patient discomfort and anxiety associated with mechanical ventilation. DEX offers a potential advantage in neurosurgical procedures during which an early neurological evaluation has to be performed on an intubated patient, because of its opioid-sparing effects, minimal respiratory depression, and the easy arousability on verbal stimulation.
An immediate postoperative neurological examination was completed successfully on two intubated patients maintained on DEX (infusion rate, 0.2 g/kg/h) after a multilevel cervical procedure (15) . Urban et al. (88) compared the ability to perform a neurological examination on 20 ventilated patients after anteroposterior fusion who had been sedated with propofol versus DEX. Neurological assessment was performed more consistently on patients sedated with DEX. Three of 10 patients sedated with propofol could not complete neurological examination. Moreover, more patients in the propofol group (three versus zero) required diazepam to tolerate mechanical ventilation. Seven of 10 patients in the DEX group, however, remembered being ventilated, and 2 found it unpleasant.
Neurosurgical Intensive Care Unit
DEX has been registered for use as a sedative-analgesic in the ICU setting. Several studies have documented that it significantly reduces the need for other sedatives and analgesics, provides stable hemodynamics, and has no effect on respiratory function. In addition, DEX offers a unique quality of sedation, described as similar to normal sleep. The authors of one recent study noted that patients were in a tranquil state but were able to understand and communicate their needs upon verbal stimulation by the medical staff (including the use of pen and paper) (90) . This particular profile of sedation may allow accurate evaluation of the neuropsychological status of the mechanically ventilated patients, which is difficult to accomplish with any other sedatives currently used in the ICU. Hence, DEX may be a preferred sedative for neurosurgical patients who require a continuous assessment of their neurological status.
Although multiple trials have evaluated the use of DEX in the ICU setting, there has been no study designed specifically to evaluate this drug in the neurosurgical population. There is only one report on the use of DEX for sedation in patients with traumatic brain injury (21) . DEX infusion was used safely and uneventfully in three traumatic brain injury patients with high levels of anxiety and agitation.
CONCLUSION
Are there reasons for considering DEX in the management of neurosurgical patients? Antinociception, anesthetic-sparing effects, cardiovascular stability, and minimal respiratory depression are the useful properties of this drug. In particular, DEX can provide "cooperative sedation" for functional neurosurgery requiring intraoperative neurological assessment. DEX does not increase ICP, demonstrates compatibility with neurophysiological monitoring, and may offer neuroprotection. DEX seems to reduce CBF secondary to cerebrovascular vasoconstriction. The clinical significance of this effect is uncertain at the present time. Future investigations should further evaluate the use of this drug for specific procedures and in appropriately selected patient populations.
T
his is a well-written and timely review of the available literature on the ␣ 2 -agonist DEX and its uses in neurosurgical patients (2) . DEX is a novel agent which stimulates ␣ 2 -adrenergic receptors in the locus ceruleus to provide sedation and in the spinal cord to enhance analgesia. It also causes sympatholysis via central and peripheral mechanisms. The selectivity of DEX for these sites of action has resulted in its increasing use for various neurosurgical procedures as well as in the intensive care setting, because it allows patients to remain comfortable, but arousable and cooperative. DEX is extremely useful in neurosurgical applications, as it allows for the titration of sedation without significant respiratory or hemodynamic depression. DEX allows patients to be fully engaged in awake surgeries without significant discomfort. The ability of DEX to sedate patients without interfering with electrophysiological recordings is an extremely important advantage in other types of neurosurgical procedures as well.
As is the case with any novel agent, there is a significant learning curve associated with the use of DEX. The issue of this learning curve is not discussed in the review, but is worth mentioning, as it affects experience with this drug. Learning to titrate DEX may be tricky, since both its onset and offset of action may be somewhat delayed, leading to unintentional overdosing or difficulties with arousal after cessation of treatment (1) . In addition, the dosing of DEX in micrograms/kg/ hour rather than the more common units of micrograms/kg/min has
